German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
暂无分享,去创建一个
W. Brenner | K. Rahbar | F. Mottaghy | A. Drzezga | B. Krause | A. Heinzel | U. Haberkorn | P. Bartenstein | M. Luster | P. Meyer | M. Essler | M. Schäfers | C. Kratochwil | V. Prasad | R. Baum | Matthias C Schmidt | H. Ahmadzadehfar | W. Fendler | H. Kulkarni | M. Bögemann | A. Pfestroff | U. Lützen | Marlies Marx | J. Ruf | M. Heuschkel | M. Eveslage | M. Schmidt | P. Bartenstein
[1] Oliver Sartor,et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] U. Haberkorn,et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.
[3] K. Rahbar,et al. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer , 2016, Clinical nuclear medicine.
[4] K. Rahbar,et al. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis , 2016, The Journal of Nuclear Medicine.
[5] K. Rahbar,et al. Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer , 2016, The Journal of Nuclear Medicine.
[6] T. Holland-Letz,et al. Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[7] R. Fimmers,et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer , 2016, Oncotarget.
[8] C. V. von Klot,et al. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. , 2015, European urology.
[9] K. Rahbar,et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study , 2015, EJNMMI Research.
[10] U. Haberkorn,et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.
[11] M. Schwaiger,et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.
[12] T. Holland-Letz,et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[13] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[14] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[15] M. Roethke,et al. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[16] A. Armstrong,et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] T. Holland-Letz,et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[18] G. Hildebrandt,et al. Parotid gland-recovery after radiotherapy in the head and neck region - 36 months follow-up of a prospective clinical study , 2011, Radiation oncology.
[19] E. Basch,et al. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[21] W. Heston,et al. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.
[22] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.